CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 6 enrolled
Drug / intervention
Flortaucipir F18drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02336360
NCT02336360Phase 1Completed
CompareCT.gov

A Multicenter Study to Obtain Data to Assist in Radiation Dosimetry Calculations From Subjects Enrolled in Human Studies Employing 18F-AV-1451

Avid Radiopharmaceuticals·interventional·Posted Jan 13, 2015·Updated Aug 11, 2020

In Brief

A Phase 1 clinical trial evaluating Flortaucipir F18 for Alzheimer's Disease. Completed, enrolled 6 participants across 1 site.

Detailed Summary

This study will obtain data from urine in subjects administered flortaucipir in an Avid-sponsored study to augment the calculation of radiation dosimetry estimates.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJan 13, 2015
Enrollment StartJan 1, 2015
Primary CompletionJun 1, 2015
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 11.5 years ago

Interventions

Flortaucipir F18drug

No flortaucipir administered in this study. Subjects received flortaucipir in an Avid-sponsored study.